# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6855318

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

## **CONVEYING PARTY DATA**

Name	Execution Date
ARCHA FOX	05/06/2021
RUOHAN LI	05/06/2021

## **RECEIVING PARTY DATA**

Name:	THE UNIVERSITY OF WESTERN AUSTRALIA
Street Address:	35 STIRLING HIGHWAY
City:	NEDLANDS, WA
State/Country:	AUSTRALIA
Postal Code:	6009

## **PROPERTY NUMBERS Total: 1**

Property Type	Number	
Application Number:	16483329	

## **CORRESPONDENCE DATA**

**Fax Number:** (312)474-0448

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 312-474-6300

Email: docket@marshallip.com

Correspondent Name: MARSHALL, GERSTEIN & BORUN LLP

Address Line 1: 233 S. WACKER DRIVE

Address Line 2: SUITE 6300

Address Line 4: CHICAGO, ILLINOIS 60606

ATTORNEY DOCKET NUMBER:	28594/54630
NAME OF SUBMITTER:	DAVID A. GASS
SIGNATURE:	/David A. Gass #38,153/
DATE SIGNED:	08/09/2021

## **Total Attachments: 4**

source=Executed U of WAU Assignment#page1.tif source=Executed U of WAU Assignment#page2.tif source=Executed U of WAU Assignment#page3.tif source=Executed U of WAU Assignment#page4.tif

PATENT 506808499 REEL: 057123 FRAME: 0860

#### **ASSIGNMENT**

U.S. Patent Application No. 6/483,329 (US national phase initiated August 2, 2019) National Phase of PCT/AU2018/050077 filed February 5, 2018 Title: Novel Treatment for NEAT1 Associated Disease

WHEREAS original ownership rights of Archa Fox and Ruohan Li (each individually an "Assignor") in the above referenced patent application and invention or improvements described therein belong to The University of Western Australia, with a place of business at 35 Stirling Highway, Nedlands, Western Australia 6009, AUSTRALIA ("Assignee"), by virtue of their employment and/or prior assignment;

WHEREAS the parties wish to confirm the transfer of these rights in a document suitable for recording with the United States Patent & Trademark Office;

Now, therefore, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the undersigned hereby assigns to The University of Western Australia all rights, title, and interests in and to the inventions that are disclosed in the patent application listed above (the "Application") including, but without limitation, all rights:

- (i) in and to the Application and all other applications anywhere in the world that have been or may be filed on said inventions and/or naming Assignor as an inventor of said inventions,
- (ii) in and to any and all applications claiming priority benefit of the applications listed above, including all continuations, divisionals, and continuations-in-part,
  - (iii) in and to all patents issuing on any of the foregoing,
- (iv) in and to all reissues, reexaminations, supplemental examinations, inter partes reviews, oppositions, post-grant reviews, supplementary protection certificates, and/or extensions of any of the foregoing,
- (v) to bring suit, the right to claim and retain all damages and/or seek other remedies for the past, present, and future infringement and/or misappropriation of any of the foregoing, and
- (vi) of priority including, but without limitation, the right to claim priority benefit of or to the Application and all of the foregoing.

Assignor requests the Commissioner for Patents in the United States and similar authorities outside the United States to issue said patents to and in the name of Assignee or its designee.

U.S. Patent Application No. 6/483,329 (US national phase initiated August 2, 2019) National Phase of PCT/AU2018/050077 filed February 5, 2018
Title: Novel Treatment for NEAT1 Associated Disease

Assignor warrants: (1) Assignor is the owner of all its rights, title and interests herein assigned and has the right to make this unconditional and irrevocable assignment to Assignee without obtaining any approval or permission of a third party; and (2) there are no outstanding encumbrances, liens, prior assignments, licenses, or other obligations or restrictions on the rights, title and interests herein assigned, except in favor of Assignee.

Assignor agrees to execute, upon the request of Assignee or its designee at no expense to Assignor, all applications or documents related to the inventions including, but without limitation, any oath, declaration, or affidavit relating thereto that Assignee may deem necessary or expedient, and to fully cooperate with Assignee and/or its designee to perform all affirmative acts requested to prepare, file, prosecute, maintain, defend, enforce, and vest in Assignee the rights, title, and interests assigned herein whereby said rights, title and interests will be held and enjoyed by Assignee or its designee to the full end of the term for which the intellectual property rights herein may be available as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment had not been made.

WITNESS m	ny hand this	<u></u>	day of	MAY.	2021 <del>2020</del> .
1)	aela	Agrand Town		Witnesses:	
',	Name: Archa Fox			SONG ZHAM	
	FINN MEC	Toggage.			
WITNESS n	ny hand this		day of		, 2020
				Witnesses:	
2)	Name: Ruohan Li	<u> Liniin                                </u>			
					••••

U.S. Patent Application No. 6/483,329 (US national phase initiated August 2, 2019) National Phase of PCT/AU2018/050077 filed February 5, 2018 Title: Novel Treatment for NEAT1 Associated Disease

Assignor warrants: (1) Assignor is the owner of all its rights, title and interests herein assigned and has the right to make this unconditional and irrevocable assignment to Assignee without obtaining any approval or permission of a third party; and (2) there are no outstanding encumbrances, liens, prior assignments, licenses, or other obligations or restrictions on the rights, title and interests herein assigned, except in favor of Assignee.

Assignor agrees to execute, upon the request of Assignee or its designee at no expense to Assignor, all applications or documents related to the inventions including, but without limitation, any oath, declaration, or affidavit relating thereto that Assignee may deem necessary or expedient, and to fully cooperate with Assignee and/or its designee to perform all affirmative acts requested to prepare, file, prosecute, maintain, defend, enforce, and vest in Assignee the rights, title, and interests assigned herein whereby said rights, title and interests will be held and enjoyed by Assignee or its designee to the full end of the term for which the intellectual property rights herein may be available as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment had not been made.

WITNESS m	y hand this		day of		, 2021 .
				Witnesses:	
1)	Name: Archa Fox		······		
WITNESS m	y hand this	6 <sup>th</sup>	day of	May	, 2021 .
				Witnesses:	
2)	猪鱼			Lynon Ma	R71N
	Name: Ruohan Li			dn	1.
					Manage Manage Colored
				ERIN BO	LITHO
				B. J. H	40

Page 2 of 3

28594/54630

U.S. Patent Application No. 6/483,329 (US national phase initiated August 2, 2019) National Phase of PCT/AU2018/050077 filed February 5, 2018 Title: Novel Treatment for NEAT1 Associated Disease

On behalf of Assignee, The University of Western Australia	Professor Timothy Colmer		
	Name		
	Deputy Vice-Chancellor (Research	)	
	Title		
hereby confirms Assignee's assignment.	acceptance of all rights, privileges, tit	le and interests conveyed by this	
acoignment.	Jun Coloner	10 May 2021	
	Signature	Date	